PMID- 18990559
OWN - NLM
STAT- MEDLINE
DCOM- 20090122
LR  - 20161124
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 44
IP  - 18
DP  - 2008 Dec
TI  - Targeting tumour hypoxia in breast cancer.
PG  - 2766-73
LID - 10.1016/j.ejca.2008.09.025 [doi]
AB  - Breast cancer is the most common malignancy in women. Hypoxia occurs in breast 
      cancer and in other solid tumours due to the tumour outgrowing the existing 
      vasculature. Hypoxia leads to an adaptive response, orchestrated by HIF-1 
      (hypoxia-inducible factor-1), that is crucial for tumour progression and therapy 
      resistance responsible for poor patient outcome. In several studies, downstream 
      targets of HIF-1alpha were considered as hypoxia markers. The biological 
      heterogeneity of breast cancer has been investigated through genome profiling 
      technologies. The recent data suggest that treatment outcome depends on 
      individual genetic features and that the hypoxia signature is a significant 
      prognostic factor. The identification of molecular biomarkers with the potential 
      to predict treatment outcome is essential for selecting patients to receive the 
      most beneficial therapy, and in the future may drive stratification in clinical 
      trials.
FAU - Milani, Manuela
AU  - Milani M
AD  - Department of Medical Oncology, University of Oxford, Weatherall Institute of 
      Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK.
FAU - Harris, Adrian L
AU  - Harris AL
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20081105
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/*complications/metabolism/therapy
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Hypoxia/*etiology/metabolism
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/physiology
MH  - Prognosis
MH  - Treatment Outcome
RF  - 81
EDAT- 2008/11/08 09:00
MHDA- 2009/01/23 09:00
CRDT- 2008/11/08 09:00
PHST- 2008/02/06 00:00 [received]
PHST- 2008/09/23 00:00 [accepted]
PHST- 2008/11/08 09:00 [pubmed]
PHST- 2009/01/23 09:00 [medline]
PHST- 2008/11/08 09:00 [entrez]
AID - S0959-8049(08)00716-8 [pii]
AID - 10.1016/j.ejca.2008.09.025 [doi]
PST - ppublish
SO  - Eur J Cancer. 2008 Dec;44(18):2766-73. doi: 10.1016/j.ejca.2008.09.025. Epub 2008 
      Nov 5.